When the FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in October 2024, an entire industry that had grown to serve the gap—compounding pharmacies producing GLP-1 analogs at a fraction of the branded price, telehealth platforms marketing them, and patients filling prescriptions outside the conventional pharmaceutical supply chain—lost the regulatory premise on which it had been operating. What happens next is being negotiated in court, in state legislatures, and in the slow recalibration of patient demand toward a market that once again only Eli Lilly and Novo Nordisk are licensed to supply.
The compounding episode that began in late 2022 and accelerated through 2024 was a regulatory response to a genuine supply problem. The FDA’s drug shortage list permitted 503A and 503B pharmacies to compound versions of semaglutide and tirzepatide while the branded supplies could not meet demand. The compounded versions, sold predominantly through telehealth platforms at prices ranging from a few hundred dollars per month to roughly half the branded price, reached a patient population that the branded products could not, either because of cost or because of insurance coverage limitations that excluded weight-management indications. The industry that grew up to serve this market was substantial. By mid-2024, compounded GLP-1 prescriptions in the United States were estimated in the hundreds of thousands per month.
What the compounding pharmacies were doing was, depending on one’s regulatory perspective, either a routine application of the shortage exception or a serious distortion of the FDA’s compounding framework. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients pursuant to a prescription. Section 503B permits outsourcing facilities to compound for office stock. Both pathways exist for legitimate clinical needs—custom dosages, alternative formulations for patients with allergies to excipients, supply continuity during shortages. Neither was designed to support a parallel pharmaceutical industry producing patentable molecules at scale outside the manufacturer’s distribution chain. The shortage exception, however, allowed precisely that interpretation, and the compounders moved aggressively to occupy the space.
Eli Lilly’s response to the compounding boom evolved over 2023 and 2024 from corporate concern to litigation. Lilly filed multiple lawsuits against compounding pharmacies and telehealth platforms alleging false advertising, trademark infringement, and the marketing of unapproved drugs. The cases produced settlements and injunctions against several large compounders, but the underlying market continued to function. The more consequential development was Novo Nordisk’s and Lilly’s dramatic expansion of manufacturing capacity, which by late 2024 had effectively closed the supply gap that justified the shortage designation in the first place.
When the FDA removed tirzepatide from the shortage list in October 2024, compounders had a brief grace period to wind down active prescriptions. The Outsourcing Facilities Association, representing 503B compounders, filed suit to challenge the shortage removal, arguing that the FDA had failed to properly account for downstream patient impact and inventory transition issues. A district court briefly stayed the removal in late 2024 before reinstating the FDA’s determination. Semaglutide followed a similar trajectory in early 2025. By April 2025, both shortage exceptions had been firmly closed, and compounders were operating in a much narrower regulatory window.
What that narrower window permits is genuinely contested. Section 503A still allows individualized compounding when a clinical justification—a documented allergy to an excipient, a need for a non-commercial dosage, a specific formulation requirement—exists for a particular patient. Several compounding pharmacies have pivoted toward this model, prescribing customized GLP-1 formulations under a ‘medical necessity’ rationale that may or may not survive regulatory scrutiny. The FDA has signaled, in guidance and enforcement letters, that mass-produced compounded products dressed up as individualized medicine will not be tolerated indefinitely. The agency’s enforcement bandwidth, however, is finite, and the boundary between legitimate individualized compounding and improper bulk compounding is not always crisp.
The downstream effect on patient access is the most consequential dimension of the transition. Patients who were paying $200-400 per month for compounded semaglutide are now confronting a return to branded prices that, even with manufacturer copay assistance and insurance coverage, can exceed $1,000 per month. Some patients have insurance coverage that absorbs most of this, particularly under the new IRA Part D out-of-pocket cap and the various commercial coverage expansions for obesity that Medicaid in some states is now experimenting with. Many do not, particularly the substantial population that began GLP-1 therapy through cash-pay telehealth platforms with no insurance coverage at all. The compounders’ departure from the market will leave this population with limited options.
There is a parallel regulatory question about whether the FDA’s approach to GLP-1 compounding sets a precedent that will affect future shortage-driven compounding episodes. The agency’s relatively quick removal of GLP-1s from the shortage list, combined with manufacturer manufacturing investments that arguably should have been completed earlier in the shortage cycle, suggests that future shortages of high-revenue branded products may be resolved more decisively than past ones. Whether this is a good outcome for patients is contested. Health Affairs commentators have argued that the shortage exception, applied too leniently, encourages manufacturer underinvestment and patient dependence on a regulatory accommodation that can be withdrawn at administrative discretion. The opposite argument—that the shortage exception is the only flexible response available when manufacturer supply lags clinical demand—has equal force from the patient access perspective.
What the compounding episode obscured, and what becomes more visible now that the shortage exceptions have closed, is the underlying question of why GLP-1 prices are what they are. The list price of branded semaglutide and tirzepatide reflects a combination of substantial R&D recovery on the underlying molecules, recouping manufacturing investments made during the shortage scale-up, and the commercial value the manufacturers can extract from a market with limited current alternatives. The compounded prices, often a tenth or less of the branded prices, suggested that the active pharmaceutical ingredient itself can be produced and dispensed at much lower cost. This is true. It is also misleading, because the compounded products did not bear the development cost or the manufacturing scale investment that produced the regulatory pathway in the first place. Whether the difference between the compounded price and the branded price represents fair compensation for innovation or excess rent extraction depends on inputs that nobody outside the manufacturers’ finance departments has the data to assess.
The longer-term trajectory of GLP-1 economics is being shaped now, in early 2026, by several parallel developments. The IRA’s second round of negotiation includes Ozempic. Generic semaglutide could enter the US market potentially in 2031 when key patents expire, though formulation patents may extend the originator’s exclusive period further. Several next-generation GLP-1s and combination products are advancing through clinical development, including oral formulations that may eventually reduce manufacturing complexity and per-dose cost. Compounding has, in this telling, played a particular role: it filled a gap, gave patients a glimpse of what cash-pay GLP-1 access at lower prices could look like, and established a price reference point that branded manufacturers are now pressured to address through coupons, telehealth partnerships, and tiered access programs.
What the compounding industry’s compressed lifecycle has demonstrated, perhaps more than any other recent episode, is how quickly a regulatory accommodation can produce, sustain, and then unwind a parallel commercial market. The patients who relied on it are now adjusting. The clinicians who built practices around it are diversifying. The manufacturers who lost share to it are recovering. The lessons—about how shortage policy interacts with high-demand novel therapeutics, about whether the existing regulatory framework can absorb the kind of demand spikes that GLP-1s produced, about what patient access actually looks like when a single class of drugs becomes the most prescribed in the country—will reshape future regulatory responses in ways that are not yet predictable. The compounding episode has ended. The questions it raised about access, pricing, and the geometry of pharmaceutical innovation are still in the air.
